Literature DB >> 22578413

CT scans of the chest in carriers of human T-cell lymphotropic virus type 1: presence of interstitial pneumonia.

Tsuneo Yamashiro1, Hisashi Kamiya, Tetsuhiro Miyara, Shinji Gibo, Kazuhiko Ogawa, Tamaki Akamine, Hidekazu Moromizato, Satomi Yara, Sadayuki Murayama.   

Abstract

RATIONALE AND
OBJECTIVES: To evaluate pulmonary findings on computed tomography (CT) scans in carriers of human T-lymphotropic virus type 1 (HTLV-1).
MATERIALS AND METHODS: This retrospective study was approved by the Institutional Review Board at each institution, and informed consent was waived. Patients who were diagnosed with adult T-cell lymphoma/leukemia or collagen vascular disease were excluded from the study. Chest CT of 106 HTLV-1 carriers (54 females and 52 males; age range 44-94 years) were initially evaluated by two chest radiologists. Assessed CT findings included centrilobular nodules, thickening of bronchovascular bundles, ground-glass opacity, bronchiectasis, interlobular septal thickening, consolidation, honeycombing, crazy-paving appearance, enlarged lymph nodes, pleural effusion, and pericardial effusion. Three chest radiologists secondarily evaluated the CT scans with the abnormal findings to judge the presence of interstitial pneumonia patterns or a bronchiolitis/bronchitis pattern.
RESULTS: Abnormal CT findings were found in 65 (61.3%) patients, including ground-glass opacity (n = 33), bronchiectasis (n = 28), centrilobular nodules (n = 25), and interlobular septal thickening (n = 19). Honeycombing (n = 5) and crazy-paving appearance (n = 3) were also observed. Based on the CT findings, 10 subjects were diagnosed with interstitial pneumonia (usual interstitial pneumonia pattern, n = 3; nonspecific interstitial pneumonia pattern, n = 5; organizing pneumonia pattern, n = 2; respectively). Twenty subjects were diagnosed with the bronchitis/bronchiolitis pattern.
CONCLUSION: Although the bronchiolitis/bronchitis pattern is predominant on chest CT in HTLV-1 carriers, the HTLV-1 infection is associated with various interstitial pneumonias.
Copyright © 2012 AUR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22578413     DOI: 10.1016/j.acra.2012.03.020

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  22 in total

1.  Triple Therapy with Prednisolone, Pegylated Interferon and Sodium Valproate Improves Clinical Outcome and Reduces Human T-Cell Leukemia Virus Type 1 (HTLV-1) Proviral Load, Tax and HBZ mRNA Expression in Patients with HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis.

Authors:  Reza Boostani; Rosita Vakili; Samane Sadat Hosseiny; Ali Shoeibi; Bahare Fazeli; Mohammad Mehdi Etemadi; Faeze Sabet; Narges Valizade; Seyed Abdolrahim Rezaee
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

2.  Altered Expression of Cell Cycle Regulators in Adult T-Cell Leukemia/ Lymphoma Patients.

Authors:  Reza Torshizi; Ehsan Ghayour Karimani; Kobra Etminani; Mohammad Mehdi Akbarin; Khadijeh Jamialahmadi; Abbas Shirdel; Hossein Rahimi; Abolghasem Allahyari; Amin Golabpour; Houshang Rafatpanah
Journal:  Rep Biochem Mol Biol       Date:  2017-10

Review 3.  Clinical and Public Health Implications of Human T-Lymphotropic Virus Type 1 Infection.

Authors:  Nicolas Legrand; Skye McGregor; Rowena Bull; Sahar Bajis; Braulio Mark Valencia; Amrita Ronnachit; Lloyd Einsiedel; Antoine Gessain; John Kaldor; Marianne Martinello
Journal:  Clin Microbiol Rev       Date:  2022-02-23       Impact factor: 50.129

4.  Diffuse panbronchiolitis after humanized anti-CCR4 monoclonal antibody therapy for relapsed adult T-cell leukemia/lymphoma.

Authors:  Koji Kato; Toshihiro Miyamoto; Akihiko Numata; Takashi Nakaike; Hideyo Oka; Ayano Yurino; Takuro Kuriyama; Yasuo Mori; Satoshi Yamasaki; Tsuyoshi Muta; Katsuto Takenaka; Hiromi Iwasaki; Takanori Teshima; Koichi Akashi
Journal:  Int J Hematol       Date:  2013-02-09       Impact factor: 2.490

5.  Higher human T-lymphotropic virus type 1 subtype C proviral loads are associated with bronchiectasis in indigenous australians: results of a case-control study.

Authors:  Lloyd Einsiedel; Olivier Cassar; Emma Goeman; Tim Spelman; Virginia Au; Saba Hatami; Sheela Joseph; Antoine Gessain
Journal:  Open Forum Infect Dis       Date:  2014-05-28       Impact factor: 3.835

6.  Clinical associations of Human T-Lymphotropic Virus type 1 infection in an indigenous Australian population.

Authors:  Lloyd Einsiedel; Tim Spelman; Emma Goeman; Olivier Cassar; Mick Arundell; Antoine Gessain
Journal:  PLoS Negl Trop Dis       Date:  2014-01-16

7.  Human T-lymphotropic Virus Type I (HTLV-I) Proviral Load and Clinical Features in Iranian HAM/TSP Patients: Comparison of HTLV-I Proviral Load in HAM/TSP Patients.

Authors:  Rosita Vakili; Faezeh Sabet; Sanaz Aahmadi; Reza Boostani; Houshang Rafatpanah; Ali Shamsian; S A Rahim Rezaee
Journal:  Iran J Basic Med Sci       Date:  2013-03       Impact factor: 2.699

8.  Assessment of HTLV-I proviral load, HIV viral load and CD4 T cell count in infected subjects; with an emphasis on viral replication in co-infection.

Authors:  Hossein Rahimi; Seyyed Abdolrahim Rezaee; Narges Valizade; Rosita Vakili; Houshang Rafatpanah
Journal:  Iran J Basic Med Sci       Date:  2014-01       Impact factor: 2.699

9.  Comparison of HTLV-I Proviral Load in Adult T Cell Leukemia/Lymphoma (ATL), HTLV-I-Associated Myelopathy (HAM-TSP) and Healthy Carriers.

Authors:  Mohammad Mehdi Akbarin; Hossein Rahimi; Tahereh Hassannia; Ghazaleh Shoja Razavi; Faezeh Sabet; Abbas Shirdel
Journal:  Iran J Basic Med Sci       Date:  2013-03       Impact factor: 2.699

Review 10.  Human T Lymphotropic Virus Type I (HTLV-I) Oncogenesis: Molecular Aspects of Virus and Host Interactions in Pathogenesis of Adult T cell Leukemia/Lymphoma (ATL).

Authors:  Sanaz Ahmadi Ghezeldasht; Abbas Shirdel; Mohammad Ali Assarehzadegan; Tahereh Hassannia; Hosian Rahimi; Rahele Miri; S A Rahim Rezaee
Journal:  Iran J Basic Med Sci       Date:  2013-03       Impact factor: 2.699

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.